VANCOUVER, BC / ACCESS Newswire / January 29, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce positive interim resu ...
Semaglutide, the active ingredient in the weight-loss medications Ozempic and Wegovy, offers substantial cardiovascular ...
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in patients with type 2 diabetes (T2D) inadequately ...
Feb 4 (Reuters) - Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the ...
The combination of cagrilintide 2.4 mg and semaglutide 2.4 mg was superior to semaglutide alone for weight loss and HbA1c ...
Feb 2 (Reuters) - Novo Nordisk said on Monday its experimental next-generation weight-loss drug CagriSema showed greater ...
Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema ...
ScienceAlert on MSN
Semaglutide pill shows heart benefits in one key group, study finds
Taking oral semaglutide may reduce heart-related hospitalizations and deaths among those with a history of heart failure and ...
Zacks Investment Research on MSN
NVO's CagriSema outshines semaglutide in Phase III diabetes study
Novo Nordisk NVO announced positive top-line data from a late-stage study in its global REIMAGINE clinical study program for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results